The median value of Myl9 in this cohort was approximately 170–200 ng/mL (Fig. 2), which is greater than 39.4 ng/mL, the cutoff value determined by comparing healthy controls and acute COVID-19 patients.12 This evidence concerns the gene MYL9 and COVID-19.